Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | FAP | Q12884 | 1/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 2/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.41 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.41 |
| ▸ | NTSR2 | O95665 | 7/20 | 0.40 |
| ▸ | NTSR1 | P30989 | 7/20 | 0.40 |
| ▸ | SORT1 | Q99523 | 7/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8117318 | 0.89 | SLC6A2 (0.49) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL5275743 | 0.87 | DPP4 (0.51) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL5275753 | 0.87 | DPP4 (0.51) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL8366873 | 0.79 | SLC6A2 (0.50) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL30112895 | 0.77 | SLC6A2 (0.57) | ACESLC6A2NTSR2NTSR1SORT1 | |
| SCHEMBL28256389 | 0.76 | ACE (0.60) | ACEACE2SLC6A2 | |
| SCHEMBL30052918 | 0.76 | ACE (0.60) | ACEACE2SLC6A2 | |
| SCHEMBL6261419 | 0.75 | DPP4 (0.56) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL15373369 | 0.75 | POLB (0.44) | ACEACE2ELANEFKBP1A | |
| SCHEMBL8103315 | 0.74 | NTSR1 (0.49) | NTSR2NTSR1SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007143822-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-21 | — | — | WO | disclosed |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-20 | — | — | US | disclosed |
| WO-2006102760-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HAT1 | DPP4 2557/4885FAP 2626/4885DPP8 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.